EpicentRx announces positive results from phase 1 trial of RRx-001 as first-line treatment in newly diagnosed glioblastoma

This article was originally published here

The late-breaking data were presented by Nicholas Butowski, M.D., a principal investigator on the trial and Professor of Neurological Surgery at the University of California San Francisco Weill

The post EpicentRx announces positive results from phase 1 trial of RRx-001 as first-line treatment in newly diagnosed glioblastoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply